Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-01

AUTHORS

Angelica L. Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell D. Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum

ABSTRACT

PURPOSE: To characterize the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast cancer (EBC), assess the impact of covariates on trastuzumab PK, and evaluate fixed (nonweight-based) dosing for the SC regimen administrated via handheld syringe. METHODS: Serum trastuzumab concentrations from 595 patients with HER2-positive EBC in the HannaH study (fixed 600 mg SC trastuzumab or weight-based IV trastuzumab) were analyzed using nonlinear mixed-effects modeling. Multiple logistic regression was used to assess the exposure-response relationships between PK, efficacy [pathologic complete response (pCR)], and safety [grade ≥3 adverse events (AEs)]. RESULTS: Trastuzumab PK was described by a two-compartment model with parallel linear and nonlinear elimination and first-order SC absorption, with a bioavailability of 77 %. Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L. Body weight and alanine transaminase, while showing significant effects on PK, only explained 8% of the variability in CL. Exposure-response analyses showed no relationship between PK, pCR, and grade ≥3 AEs for either regimen. CONCLUSION: A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy. Fixed dosing is further supported by lack of an exposure-response relationship between PK, pCR, and grade ≥3 AEs. No dose adjustment per patient factors is required within the ranges studied. More... »

PAGES

77-88

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-015-2922-5

DOI

http://dx.doi.org/10.1007/s00280-015-2922-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011349790

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26645407


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Logistic Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nonlinear Dynamics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Syringes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quartino", 
        "givenName": "Angelica L.", 
        "id": "sg:person.01320560307.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320560307.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Roche, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hillenbach", 
        "givenName": "Carina", 
        "id": "sg:person.015756542174.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015756542174.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Jing", 
        "id": "sg:person.013666353540.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666353540.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Quantitative Solutions, Inc., Menlo Park, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Hanbin", 
        "id": "sg:person.01034251740.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034251740.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Quantitative Solutions, Inc., Menlo Park, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wada", 
        "givenName": "Russell D.", 
        "id": "sg:person.01222341641.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222341641.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Visich", 
        "givenName": "Jennifer", 
        "id": "sg:person.01246121610.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246121610.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Chunze", 
        "id": "sg:person.01203164460.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203164460.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Roche, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heinzmann", 
        "givenName": "Dominik", 
        "id": "sg:person.01325427663.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325427663.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jin", 
        "givenName": "Jin Y.", 
        "id": "sg:person.016026247332.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016026247332.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., California, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lum", 
        "givenName": "Bert L.", 
        "id": "sg:person.0716757142.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757142.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01061469", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000869925", 
          "https://doi.org/10.1007/bf01061469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001624052", 
          "https://doi.org/10.1038/sj.onc.1202526"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001624052", 
          "https://doi.org/10.1038/sj.onc.1202526"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11535960-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006906500", 
          "https://doi.org/10.2165/11535960-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11535960-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006906500", 
          "https://doi.org/10.2165/11535960-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/psp.2013.63", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016431316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2005.01.041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020413700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(12)70329-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021020860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021357627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-1026-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034184349", 
          "https://doi.org/10.1007/s00280-005-1026-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-1026-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034184349", 
          "https://doi.org/10.1007/s00280-005-1026-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-009-9133-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046129728", 
          "https://doi.org/10.1208/s12248-009-9133-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270012436560", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047012014"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2009.00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048163683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2009.00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048163683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0032-1321831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057270394"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cpp48297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072835721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074519294", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077362565", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-01", 
    "datePublishedReg": "2016-01-01", 
    "description": "PURPOSE: To characterize the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast cancer (EBC), assess the impact of covariates on trastuzumab PK, and evaluate fixed (nonweight-based) dosing for the SC regimen administrated via handheld syringe.\nMETHODS: Serum trastuzumab concentrations from 595 patients with HER2-positive EBC in the HannaH study (fixed 600 mg SC trastuzumab or weight-based IV trastuzumab) were analyzed using nonlinear mixed-effects modeling. Multiple logistic regression was used to assess the exposure-response relationships between PK, efficacy [pathologic complete response (pCR)], and safety [grade \u22653 adverse events (AEs)].\nRESULTS: Trastuzumab PK was described by a two-compartment model with parallel linear and nonlinear elimination and first-order SC absorption, with a bioavailability of 77 %. Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 \u00b5g/mL; the estimate for central volume of distribution was 2.9 L. Body weight and alanine transaminase, while showing significant effects on PK, only explained 8% of the variability in CL. Exposure-response analyses showed no relationship between PK, pCR, and grade \u22653 AEs for either regimen.\nCONCLUSION: A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 \u03bcg/mL for the 5th-95th percentiles) above the historical target concentration of 20 \u03bcg/mL for efficacy. Fixed dosing is further supported by lack of an exposure-response relationship between PK, pCR, and grade \u22653 AEs. No dose adjustment per patient factors is required within the ranges studied.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-015-2922-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "77"
      }
    ], 
    "name": "Population pharmacokinetic and exposure\u2013response analysis for trastuzumab administered using a subcutaneous \u201cmanual syringe\u201d injection or intravenously in women with HER2-positive early breast cancer", 
    "pagination": "77-88", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3613125d0734f8f08217f8f570c1db9b815ad1e1764cdb2f2d3dec16afd6b7a8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26645407"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-015-2922-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011349790"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-015-2922-5", 
      "https://app.dimensions.ai/details/publication/pub.1011349790"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000367_0000000367/records_88230_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-015-2922-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2922-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2922-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2922-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2922-5'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      21 PREDICATES      59 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-015-2922-5 schema:about N19e5d354fe284c4993c717e4b5a2f947
2 N20183f2b44d64a88bb8e811fe8d6c42e
3 N268d8ac5e0a44636b5d098b1bdc67197
4 N4078b61d8b2b423eae12149c098abfd6
5 N40d52d01632840109d1fb7ca4a1159b6
6 N4762df90e9794944980d066a5a1a53a0
7 N4b84ba7d12ab49e4b12070d4fd846ea5
8 N617b90094e9c40d6bfd8fac7e3d87aca
9 N641c6dd532f44635814bf7e6d3bea15c
10 N7fd14ec512244002ae88929fc9e64f8f
11 N80f6945f62694c858dc64db77ac5b41b
12 Nb3bafcea03364da49c88a1d8f4f3fcce
13 Nbfddfa400f5f4ef2ad432c4dbc063aef
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author N07ecbfc47c98478ebd8f93bc8b20f054
17 schema:citation sg:pub.10.1007/bf01061469
18 sg:pub.10.1007/s00280-005-1026-z
19 sg:pub.10.1038/sj.onc.1202526
20 sg:pub.10.1208/s12248-009-9133-0
21 sg:pub.10.2165/11531280-000000000-00000
22 sg:pub.10.2165/11535960-000000000-00000
23 https://app.dimensions.ai/details/publication/pub.1074519294
24 https://app.dimensions.ai/details/publication/pub.1077362565
25 https://doi.org/10.1016/j.canlet.2005.01.041
26 https://doi.org/10.1016/s1470-2045(12)70329-7
27 https://doi.org/10.1038/psp.2013.63
28 https://doi.org/10.1055/s-0032-1321831
29 https://doi.org/10.1093/annonc/mdu524
30 https://doi.org/10.1111/j.1476-5381.2009.00190.x
31 https://doi.org/10.1177/0091270012436560
32 https://doi.org/10.1200/jco.1999.17.9.2639
33 https://doi.org/10.5414/cpp48297
34 schema:datePublished 2016-01
35 schema:datePublishedReg 2016-01-01
36 schema:description PURPOSE: To characterize the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast cancer (EBC), assess the impact of covariates on trastuzumab PK, and evaluate fixed (nonweight-based) dosing for the SC regimen administrated via handheld syringe. METHODS: Serum trastuzumab concentrations from 595 patients with HER2-positive EBC in the HannaH study (fixed 600 mg SC trastuzumab or weight-based IV trastuzumab) were analyzed using nonlinear mixed-effects modeling. Multiple logistic regression was used to assess the exposure-response relationships between PK, efficacy [pathologic complete response (pCR)], and safety [grade ≥3 adverse events (AEs)]. RESULTS: Trastuzumab PK was described by a two-compartment model with parallel linear and nonlinear elimination and first-order SC absorption, with a bioavailability of 77 %. Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L. Body weight and alanine transaminase, while showing significant effects on PK, only explained 8% of the variability in CL. Exposure-response analyses showed no relationship between PK, pCR, and grade ≥3 AEs for either regimen. CONCLUSION: A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy. Fixed dosing is further supported by lack of an exposure-response relationship between PK, pCR, and grade ≥3 AEs. No dose adjustment per patient factors is required within the ranges studied.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N22a962f132d744f4bfea6a0e0350e1cd
41 N9c2b7212388143dfac20a20b19bf35ef
42 sg:journal.1088364
43 schema:name Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
44 schema:pagination 77-88
45 schema:productId N0ac33084601a49d6912c38f36a6cb614
46 N4023691b5a824b92b875daf117f0600f
47 N93ff6d2b924845f49b1e10d8c102c727
48 Ndc84b63468a04e3096b8e33e328c859f
49 Nea8b4f85057744e6b8b00ff33dd62053
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011349790
51 https://doi.org/10.1007/s00280-015-2922-5
52 schema:sdDatePublished 2019-04-11T13:08
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N5a2a91b070874f248b90e762a973e404
55 schema:url http://link.springer.com/10.1007%2Fs00280-015-2922-5
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N07ecbfc47c98478ebd8f93bc8b20f054 rdf:first sg:person.01320560307.61
60 rdf:rest Nb6ea91dd94674bff8ce252ea98642195
61 N0ac33084601a49d6912c38f36a6cb614 schema:name doi
62 schema:value 10.1007/s00280-015-2922-5
63 rdf:type schema:PropertyValue
64 N19e5d354fe284c4993c717e4b5a2f947 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Receptor, ErbB-2
66 rdf:type schema:DefinedTerm
67 N20183f2b44d64a88bb8e811fe8d6c42e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Nonlinear Dynamics
69 rdf:type schema:DefinedTerm
70 N22a962f132d744f4bfea6a0e0350e1cd schema:volumeNumber 77
71 rdf:type schema:PublicationVolume
72 N22f41e99e7314fb499ae90c01c8df254 rdf:first sg:person.01246121610.06
73 rdf:rest Na67f541830ee408bacab04195a6dc07d
74 N268d8ac5e0a44636b5d098b1bdc67197 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 N4023691b5a824b92b875daf117f0600f schema:name dimensions_id
78 schema:value pub.1011349790
79 rdf:type schema:PropertyValue
80 N4078b61d8b2b423eae12149c098abfd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Syringes
82 rdf:type schema:DefinedTerm
83 N40d52d01632840109d1fb7ca4a1159b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Tissue Distribution
85 rdf:type schema:DefinedTerm
86 N4762df90e9794944980d066a5a1a53a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Infusions, Intravenous
88 rdf:type schema:DefinedTerm
89 N4b84ba7d12ab49e4b12070d4fd846ea5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Injections, Subcutaneous
91 rdf:type schema:DefinedTerm
92 N57afcdd59d8e406289b35cdc10c97ca0 rdf:first sg:person.01325427663.28
93 rdf:rest N91db9ae15a334022947e19e4a4472cf3
94 N5a2a91b070874f248b90e762a973e404 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N617b90094e9c40d6bfd8fac7e3d87aca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Biological Availability
98 rdf:type schema:DefinedTerm
99 N641c6dd532f44635814bf7e6d3bea15c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Trastuzumab
101 rdf:type schema:DefinedTerm
102 N667f8c818daf4c9da65f606653a8986e rdf:first sg:person.0716757142.45
103 rdf:rest rdf:nil
104 N77fd625064764650ace78bb1b8029a2a rdf:first sg:person.01222341641.71
105 rdf:rest N22f41e99e7314fb499ae90c01c8df254
106 N7fd14ec512244002ae88929fc9e64f8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Breast Neoplasms
108 rdf:type schema:DefinedTerm
109 N80f6945f62694c858dc64db77ac5b41b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Antineoplastic Agents
111 rdf:type schema:DefinedTerm
112 N91db9ae15a334022947e19e4a4472cf3 rdf:first sg:person.016026247332.04
113 rdf:rest N667f8c818daf4c9da65f606653a8986e
114 N93ff6d2b924845f49b1e10d8c102c727 schema:name pubmed_id
115 schema:value 26645407
116 rdf:type schema:PropertyValue
117 N9c2b7212388143dfac20a20b19bf35ef schema:issueNumber 1
118 rdf:type schema:PublicationIssue
119 N9fc2ce08eaff4095b52a139fe37eca02 rdf:first sg:person.01034251740.93
120 rdf:rest N77fd625064764650ace78bb1b8029a2a
121 Na67f541830ee408bacab04195a6dc07d rdf:first sg:person.01203164460.15
122 rdf:rest N57afcdd59d8e406289b35cdc10c97ca0
123 Nb3bafcea03364da49c88a1d8f4f3fcce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Logistic Models
125 rdf:type schema:DefinedTerm
126 Nb6ea91dd94674bff8ce252ea98642195 rdf:first sg:person.015756542174.42
127 rdf:rest Nf3551af3458e4b4aa0e9959eb6422ad3
128 Nbfddfa400f5f4ef2ad432c4dbc063aef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Female
130 rdf:type schema:DefinedTerm
131 Ndc84b63468a04e3096b8e33e328c859f schema:name nlm_unique_id
132 schema:value 7806519
133 rdf:type schema:PropertyValue
134 Nea8b4f85057744e6b8b00ff33dd62053 schema:name readcube_id
135 schema:value 3613125d0734f8f08217f8f570c1db9b815ad1e1764cdb2f2d3dec16afd6b7a8
136 rdf:type schema:PropertyValue
137 Nedb8394f63524b2a9b633bd3e233e6af schema:name Quantitative Solutions, Inc., Menlo Park, CA, USA
138 rdf:type schema:Organization
139 Nedc1e193dd8a40eebdd2a4e22605a405 schema:name Quantitative Solutions, Inc., Menlo Park, CA, USA
140 rdf:type schema:Organization
141 Nf3551af3458e4b4aa0e9959eb6422ad3 rdf:first sg:person.013666353540.75
142 rdf:rest N9fc2ce08eaff4095b52a139fe37eca02
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
147 schema:name Public Health and Health Services
148 rdf:type schema:DefinedTerm
149 sg:journal.1088364 schema:issn 0344-5704
150 1432-0843
151 schema:name Cancer Chemotherapy and Pharmacology
152 rdf:type schema:Periodical
153 sg:person.01034251740.93 schema:affiliation Nedb8394f63524b2a9b633bd3e233e6af
154 schema:familyName Li
155 schema:givenName Hanbin
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034251740.93
157 rdf:type schema:Person
158 sg:person.01203164460.15 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
159 schema:familyName Li
160 schema:givenName Chunze
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203164460.15
162 rdf:type schema:Person
163 sg:person.01222341641.71 schema:affiliation Nedc1e193dd8a40eebdd2a4e22605a405
164 schema:familyName Wada
165 schema:givenName Russell D.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222341641.71
167 rdf:type schema:Person
168 sg:person.01246121610.06 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
169 schema:familyName Visich
170 schema:givenName Jennifer
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246121610.06
172 rdf:type schema:Person
173 sg:person.01320560307.61 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
174 schema:familyName Quartino
175 schema:givenName Angelica L.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320560307.61
177 rdf:type schema:Person
178 sg:person.01325427663.28 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
179 schema:familyName Heinzmann
180 schema:givenName Dominik
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325427663.28
182 rdf:type schema:Person
183 sg:person.013666353540.75 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
184 schema:familyName Li
185 schema:givenName Jing
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013666353540.75
187 rdf:type schema:Person
188 sg:person.015756542174.42 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
189 schema:familyName Hillenbach
190 schema:givenName Carina
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015756542174.42
192 rdf:type schema:Person
193 sg:person.016026247332.04 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
194 schema:familyName Jin
195 schema:givenName Jin Y.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016026247332.04
197 rdf:type schema:Person
198 sg:person.0716757142.45 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
199 schema:familyName Lum
200 schema:givenName Bert L.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757142.45
202 rdf:type schema:Person
203 sg:pub.10.1007/bf01061469 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000869925
204 https://doi.org/10.1007/bf01061469
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/s00280-005-1026-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1034184349
207 https://doi.org/10.1007/s00280-005-1026-z
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/sj.onc.1202526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001624052
210 https://doi.org/10.1038/sj.onc.1202526
211 rdf:type schema:CreativeWork
212 sg:pub.10.1208/s12248-009-9133-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046129728
213 https://doi.org/10.1208/s12248-009-9133-0
214 rdf:type schema:CreativeWork
215 sg:pub.10.2165/11531280-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033453107
216 https://doi.org/10.2165/11531280-000000000-00000
217 rdf:type schema:CreativeWork
218 sg:pub.10.2165/11535960-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006906500
219 https://doi.org/10.2165/11535960-000000000-00000
220 rdf:type schema:CreativeWork
221 https://app.dimensions.ai/details/publication/pub.1074519294 schema:CreativeWork
222 https://app.dimensions.ai/details/publication/pub.1077362565 schema:CreativeWork
223 https://doi.org/10.1016/j.canlet.2005.01.041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020413700
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/s1470-2045(12)70329-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021020860
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1038/psp.2013.63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016431316
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1055/s-0032-1321831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057270394
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/annonc/mdu524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021357627
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1111/j.1476-5381.2009.00190.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048163683
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1177/0091270012436560 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047012014
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.1999.17.9.2639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549894
238 rdf:type schema:CreativeWork
239 https://doi.org/10.5414/cpp48297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072835721
240 rdf:type schema:CreativeWork
241 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
242 schema:name Roche, Basel, Switzerland
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
245 schema:name Genentech, Inc., California, CA, USA
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...